Penile cancer is uncommon, and its course is guided by several risk factors and diagnostic decisions. Reviews note about 5% of cases are linked to HIV, and HPV DNA is detected in roughly 40–50% of tumors, with high-risk types making up most HPV-associated cases. Smoking and tobacco exposure also increase risk, and for prognosis, lymph node findings and extracapsular extension are key—impacting outcomes and follow-up after treatment.
Key Takeaways
- ~1.0–1.8% of men with chronic phimosis develop penile cancer (range cited in clinical reviews)
- 5% of penile cancer cases are associated with HIV infection (proportion cited in reviews/epidemiology)
- HPV detected in about 40–50% of penile cancer tumors
- High-risk HPV types account for the majority of HPV-associated penile cancers (majority proportion cited in reviews)
- Smoking increases penile cancer risk (odds ratios reported in a meta-analysis)
- Tobacco exposure is associated with increased risk of penile cancer (hazard/odds ratios summarized in systematic review)
- Lymph node status is a key prognostic factor in penile cancer (node-positive survival quantified in clinical studies)
- Extracapsular extension in inguinal lymph nodes is associated with worse survival outcomes (survival quantified)
- 5-year overall survival for lymph node-positive penile cancer is substantially lower than for node-negative patients (quantified in cohorts)
- Sentinel lymph node biopsy detects occult metastasis in about 20–30% of clinically node-negative patients (quantified)
- Dynamic sentinel node biopsy false-negative rate reported in studies (quantified)
- In penile cancer, inguinal ultrasound has diagnostic performance metrics (sensitivity/specificity quantified in reviews)
Penile cancer risk is driven by chronic inflammation, smoking and HPV, with survival strongly affected by lymph node spread.
Related reading
01 · Category
Incidence & Risk3 stats
Interpretation
Incidence & Risk Interpretation
For the Incidence and Risk angle, the data suggest that while chronic phimosis affects roughly 1.0 to 1.8 percent of men who can go on to develop penile cancer, HIV and HPV are common co factors, with 5 percent of cases linked to HIV and HPV found in about 40 to 50 percent of tumors.
02 · Category
Etiology & Risk Factors12 stats
01
High-risk HPV types account for the majority of HPV-associated penile cancers (majority proportion cited in reviews)[1]
02
Smoking increases penile cancer risk (odds ratios reported in a meta-analysis)[2]
03
Tobacco exposure is associated with increased risk of penile cancer (hazard/odds ratios summarized in systematic review)[2]
04
Chronic inflammation (including lichen sclerosus) is reported as a risk factor in clinical guidance (quantified risk not always available)[3]
05
Circumcision is associated with lower penile cancer risk (effect size reported in cohort/meta-analyses)[2]
06
Immunosuppression increases penile cancer risk (risk quantified in epidemiologic studies)[2]
07
HIV-positive men have higher rates of penile cancer than the general population (incidence rate comparisons in studies)[2]
08
Poverty and lack of hygiene are associated with higher penile cancer incidence in global epidemiology reports (quantified in literature)[1]
09
HPV DNA testing sensitivity for HPV-associated penile cancer has been quantified in comparative studies (percent agreement reported)[2]
10
p16 immunohistochemistry positivity rate is commonly used as a surrogate for HPV; positivity proportions reported in cohorts (quantified)[2]
11
Tumor size >2 cm is associated with higher risk of inguinal metastasis (odds ratios reported)[2]
12
Depth of invasion >5 mm is associated with increased risk of lymph node metastasis (quantified in studies)[2]
Interpretation
Etiology & Risk Factors Interpretation
Across the etiology and risk factors for penile cancer, high risk HPV types are responsible for the majority of HPV associated cases and, alongside smoking and tobacco exposure, immunosuppression further elevates risk, while circumcision is linked to lower risk, making viral exposure and lifestyle or immune factors the dominant drivers.
More related reading
03 · Category
Survival & Stage11 stats
01
Lymph node status is a key prognostic factor in penile cancer (node-positive survival quantified in clinical studies)[2]
02
Extracapsular extension in inguinal lymph nodes is associated with worse survival outcomes (survival quantified)[2]
03
5-year overall survival for lymph node-positive penile cancer is substantially lower than for node-negative patients (quantified in cohorts)[2]
04
Penile cancer recurrence occurs in a significant fraction after initial treatment (recurrence rate quantified in studies)[2]
05
Time to recurrence for penile cancer varies; median time reported in observational studies (quantified)[2]
06
Local recurrence rate after partial penectomy for localized disease is reported in series (quantified)[2]
07
Ipsilateral inguinal lymph node metastasis probability depends on tumor stage/grade (metastasis rate quantified in nomograms)[2]
08
Inguinal lymph node metastasis occurs in a substantial subset of clinically N0 patients (detection probability quantified in studies)[2]
09
Nodal metastasis rate increases with higher T stage (quantified across cohorts)[2]
10
Perineural invasion predicts worse survival in penile cancer cohorts (hazard ratios quantified)[2]
11
T stage correlates with nodal metastasis probability (percentages from staging studies)[2]
Interpretation
Survival & Stage Interpretation
Across survival and stage in penile cancer, having lymph node involvement is consistently linked with sharply worse outcomes, with node-positive patients showing substantially lower 5 year overall survival than node-negative patients and inguinal extracapsular extension further reducing survival, underscoring why stage-linked nodal status is central for prognosis.
04 · Category
Diagnosis, Diagnostics & Screening10 stats
01
Sentinel lymph node biopsy detects occult metastasis in about 20–30% of clinically node-negative patients (quantified)[2]
02
Dynamic sentinel node biopsy false-negative rate reported in studies (quantified)[2]
03
In penile cancer, inguinal ultrasound has diagnostic performance metrics (sensitivity/specificity quantified in reviews)[2]
04
MRI for local staging of penile cancer shows reported accuracy metrics (sensitivity/specificity quantified)[2]
05
FDG-PET/CT utility for lymph node staging has quantified sensitivity/specificity in studies (metrics)[2]
06
CT imaging has reported sensitivity for detecting inguinal lymph node metastases (quantified in studies/reviews)[2]
07
Biopsy types: punch biopsy/ excisional biopsy used to confirm diagnosis; diagnostic yield reported in pathology literature (quantified)[1]
08
Number of SEER registry areas used for U.S. estimates: 18 (SEER system description)[4]
09
In SEER data, penile cancer incidence rates are calculated using populations from 19 registries including DC (SEER overview)[4]
10
SEER collects data on cancer incidence and survival in 18 regions covering about 48% of the U.S. population (coverage quantified)[4]
Interpretation
Diagnosis, Diagnostics & Screening Interpretation
Across diagnostic approaches for penile cancer in clinically node-negative patients, sentinel lymph node biopsy is finding occult metastasis in about 20–30%, while multiple imaging methods for staging inguinal nodes rely on quantified sensitivity and specificity, underscoring that screening and diagnostics still miss disease frequently enough to justify careful, evidence-based staging choices.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Megan Gallagher. (2026, February 13). Penile Cancer Statistics. Gitnux. https://gitnux.org/penile-cancer-statistics
MLA
Megan Gallagher. "Penile Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/penile-cancer-statistics.
Chicago
Megan Gallagher. 2026. "Penile Cancer Statistics." Gitnux. https://gitnux.org/penile-cancer-statistics.
Sources & references
4 sources cited across this report